IGF1 and breast cancer: Also, a synergistic growth inhibitory relationship between trastuzumab and inhibitors of IGF signaling including small molecule inhibitors of IGF-IR, IGFBP-3 and a dominant negative IGF-IR has been established in ErbB2 overexpressing human breast cancer cell lines [40-42].